

<b>Name:</b>	<b>Arbel, Yaron</b>
<b>Organization:</b>	Tel Aviv Medical Center, Israel
<b>Title(s):</b>	Director of the CardioVascular Research Center (CVRC) Tel-Aviv Medical Center, Israel
<b>Designations/Certificates:</b>	MD
<b>Contact Info:</b>	972-52-4266151 <a href="mailto:aronarbel@gmail.com">aronarbel@gmail.com</a> Tel Aviv Medical Center - 6 Weizmann St., Tel Aviv, 6423906, Israel

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Risk Factors for IHD
- Acute coronary syndrome
- Atherosclerosis
- Medical Devices
- Structural Heart interventions
- Heart failure

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Clinical trial design and execution
- Endothelial function

**Bio:**

Prof. Yaron Arbel is an attending interventional cardiologist and the director of the CardioVascular Research Center (CVRC) at the Tel Aviv Medical Center. Prof. Arbel has been involved in entrepreneurship for the past 15 years. He has been working as a researcher/advisor/medical director in various fields of medicine: Heart failure (Corassist- diastolic heart failure), interventional cardiology (Angioslide- preventing distal embolization), myocardial infarction (LBT-low level laser activation of bone marrow), medical informatics and wearables (CUBX- contactless hemodynamic assessment).

Prof. Yaron Arbel graduated from the Faculty of Medicine in Sackler School of Medicine at the Tel Aviv University in 2005. Later, He completed his training in Internal Medicine and Cardiology with distinction at the Tel Aviv medical center. Next, he completed a fellowship in interventional and structural cardiology at Sunnybrook medical Centre in Toronto, Canada.

He has published over 130 articles and has initiated local, national and international studies. He is a reviewer/board member in over 40 journals.

<b>Name:</b>	<b>Chew, Derek</b>
<b>Organization:</b>	Flinders University, Australia
<b>Title(s):</b>	Professor, Network Director of Cardiology
<b>Designations/Certificates:</b>	MBBS MPH PhD FRACP FACC FESC FCSANZ
<b>Contact Info:</b>	+618 8404 2001 <a href="mailto:Derek.chew@flinders.edu.au">Derek.chew@flinders.edu.au</a> Flinders University - Flinders Drive, Bedford Park, South Australia, 5042

<p><b>Specific Areas of Research Interest and Experience in Clinical Trials:</b></p> <ul style="list-style-type: none"> <li>• Acute coronary syndromes, coronary artery disease, interventional cardiology, troponin, medical decision making</li> <li>• National PI of several international studies</li> <li>• Designed, gained funding for and complete several local investigator initiated clinical trails Managed several ACS registries</li> </ul>
<p><b>Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:</b></p> <ul style="list-style-type: none"> <li>• Clinical trial design with particular interest in the statistical approach</li> <li>• Australian Implementation</li> <li>• Links to Asia/China</li> </ul>

**Bio:**

Derek Chew is a clinical and interventional cardiologist, clinical trialist and outcomes researcher in cardiovascular medicine. His training in Interventional Cardiology was at the Cleveland Clinic Foundation, and he has completed a Masters of Public Health at the Harvard School of Public Health. His PhD thesis explored the factors for improving heart attack care in Australia. He is currently Professor of Cardiology Flinders University, and is the Network Director of Cardiology for the Southern Adelaide Local Health Network. He has led the Heart Foundation/CSANZ 2016ACS Guidelines writing group and served on the European Society of Cardiology Guidelines for the management of ACS Writing committee.

<b>Name:</b>	<b>Esper, Rodrigo Barbosa</b>
<b>Organization:</b>	Prevent Senior Institute, Brazil
<b>Title(s):</b>	Chief of Internal Medicine and Cardiology Fellowships – Sancta Maggiore Hospital – Prevent Senior Research and Learning Institute Chief of Interventional Cardiology – Sancta Maggiore Hospital – Prevent Senior Health Care
<b>Designations/Certificates:</b>	MD PhD
<b>Contact Info:</b>	<a href="mailto:dresper@hotmail.com">dresper@hotmail.com</a> 55 11 999869306

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Coronary Artery Disease ( CAD)
- Diabetes and Coronary Artery Disease
- SYNTAX Score
- Risk Scores and CAD
- Acute Coronary Syndromes
- Percutaneous Coronary Intervention
- Interventional Cardiology
- Telemedicine

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- I am the head of Interventional Cardiology and Cardiology Research in Prevent Senior Brazilian Health Care System. Prevent Senior is a Brazilian private health care system with more than 370 000 patients. There are 9 Hospitals, more than 70 000 elective appointments per month. Prevent Senior Research Institute supports research in all medical areas. Prevent Senior Institute could be an important center for include and randomize patients of WINCR studies.

**Bio:**

After obtaining his medical degree from the Metropolitan University of Santos Medical School in 2004, Dr. Rodrigo Esper interned at the Hospital São Paulo of Federal University of São Paulo for an Internal Medicine Residency (2005-2006). In 2008, he completed his Cardiology residency (2007-2008) followed by an Interventional Cardiology fellowship (2009-2010) at the Heart Institute of the University of São Paulo Medical School. Under the supervision of Professor Expedito Ribeiro and Whady Hueb, Dr. Esper completed his PhD at University of São Paulo Medical School in 2015. In 2017 under the mentorship of Professor Michael Farkouh, Dr Esper won the "Early Career International Researcher Award" and "Paul Dudley White Shoolar Award" from American Heart Association (AHA). Dr Esper has the board certifications by the Brazilians Internal Medicine Society (SBCM), Cardiology Society (SBC) and Interventional Cardiology Society (SBHCI). From 2014 to 2016, Dr Esper had been the chief of the Cardiology Department at Sancta Maggiore Hospitals and Prevent Senior Group. Since 2016 Dr Esper is the chief of the Interventional Cardiology Department of the Sancta Maggiore Hospital/ Prevent Senior Group in São Paulo, Brazil. Currently Dr Rodrigo is the Coordinator of the Internal Medicine and Cardiology Fellowship at the Prevent Senior Institute. Dr Esper is also a member of the World Network for Innovation in Clinical Research (WNICR) since 2017.

<b>Name:</b>	<b>Farkouh, Michael</b>
<b>Organization:</b>	University of Toronto, Canada
<b>Title(s):</b>	Peter Munk Chair in Multinational Clinical Trials Director, Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto Vice-Chair, Research & Professor of Medicine, Department of Medicine, University of Toronto Professor of Medicine, University of Toronto
<b>Designations/Certificates:</b>	MD, MSc, FRCPC, FACC, FAHA
<b>Contact Info:</b>	416-473-6432 917-841-4379 <a href="mailto:michael.farkouh@uhn.ca">michael.farkouh@uhn.ca</a> Toronto General Hospital, 585 University Avenue, Room 4N474, Toronto, ON, M5G 2N2

<p><b>Specific Areas of Research Interest and Experience in Clinical Trials:</b></p> <ul style="list-style-type: none"> <li>• Cardiometabolic Disorders</li> <li>• Complex Chronic Diseases and their Intersection</li> </ul>
<p><b>Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:</b></p> <ul style="list-style-type: none"> <li>• Clinical Trial Design and Execution</li> </ul>

<p><b>Bio:</b></p> <p>Dr. Michael Farkouh is professor and Vice-Chair, Research, Department of Medicine, at the University of Toronto, and the Peter Munk Chair in Multinational Clinical Trials at the Peter Munk Cardiac Centre, and director of the Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research. He is an honours graduate of the Schulich School of Medicine at Western University in London, Canada. Dr. Farkouh completed his internal medicine and cardiology training at the Mayo Clinic and the Icahn School of Medicine at Mount Sinai New York, respectively, and holds an MSc in clinical epidemiology from McMaster University.</p> <p>Prior to his current appointments, Dr. Farkouh served as the founding director of the Mount Sinai Cardiovascular Clinical Trials Unit in New York City. He has published over 200 papers largely on acute coronary syndromes and cardiovascular prevention. He has mentored numerous international residents and fellows and is active in teaching clinical research methodology.</p> <p>Dr. Farkouh is internationally known for his work on the management of acute coronary syndromes in the emergency room. He has a special interest and expertise in the field of cardiovascular disease in diabetic patients. He directs numerous clinical trials on questions related to diabetes and heart disease including the NIH-sponsored FREEDOM and TAILOR-PCI trials. He chairs the committee on diabetes and heart disease at the Banting and Best Centre and at the University of Toronto and is the founder of the Worldwide Network for Innovation in Clinical Research, an international trials consortium of 10 large academic institutions. Dr. Farkouh has received the Gold Medal from John Paul II Hospital in Krakow, was elected Teacher of the Year at the Mayo Clinic, and was awarded the Jan J. Kellermann Memorial Award from the International Academy of Cardiology in 2015.</p>
---

<b>Name:</b>	<b>Godoy, Lucas Colombo</b>
<b>Organization:</b>	University of Toronto (PMCC)/University of Sao Paulo (InCor)
<b>Title(s):</b>	Cardiology Research Fellow
<b>Designations/Certificates:</b>	MD
<b>Contact Info:</b>	(416) 340-4800 x3304 <a href="mailto:lucascgodoy@uol.com.br">lucascgodoy@uol.com.br</a>

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Coronary artery disease in patients with diabetes
- Biomarkers of inflammation in patients with coronary artery disease
- Acute coronary syndromes

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Cardiology research fellow working in Toronto with Dr. Michael Farkouh and originally from Sao Paulo, Brazil. This dual country background may be useful for integrating centers in multinational clinical trials.
- Past experience as sub-investigator for multinational clinical trials in Brazil.

**Bio:**

Dr. Lucas C. Godoy obtained his Medical Degree from Paulista Medical School at the Federal University of Sao Paulo, Brazil. In 2016, he completed his medical residency training in Cardiovascular Diseases at the Heart Institute (InCor), University of Sao Paulo, Brazil, the largest Cardiology teaching and research center in South America. He worked as a junior coordinator of the Cardiology training program, and also as an attending physician at InCor.

Dr. Godoy has a long-time commitment to clinical research, and recently he completed the course “Principles and Practice of Clinical Research,” offered by Harvard T.H. Chan School of Public Health, receiving a “Clinical Research Scholar Award” in recognition of “outstanding performance” in that course.

Dr. Godoy is currently employed as a Cardiology Research Fellow in the Peter Munk Cardiac Centre, at the University of Toronto, working under direct supervision of Dr. Michael Farkouh. During his training years, Dr. Godoy has received three research awards and presented his works in many congresses in Brazil and abroad. His main clinical research focus is on coronary disease in patients with type-2 diabetes and the relationship between atherosclerosis and inflammation.

<b>Name:</b>	<b>Goodman, Shaun</b>
<b>Organization:</b>	Canadian VIGOUR Centre (CVC) and Canadian Heart Research Centre (CHRC), Canada
<b>Title(s):</b>	Co-Director (CVC) and Consultant (CHRC)
<b>Designations/Certificates:</b>	MD, MSc, FRCPC, FESC, FACC, FAHA, FCCS
<b>Contact Info:</b>	416 930 6849 <a href="mailto:goodmans@chrc.net">goodmans@chrc.net</a> St. Michael's Hospital – 30 Bond Street, Toronto, ON M5B 1W8

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Ischemic heart disease (acute and chronic)
- Atrial fibrillation
- Diabetes
- Dyslipidemia

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Contacts across Canada (and some internationally) that would facilitate engagement in clinical trials/studies
- Relationships with academic research organizations who can provide research infrastructure to operationalize clinical research projects

**Bio:**

Dr. Shaun Goodman is a Staff Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael's Hospital. He is a Professor and Heart & Stroke Foundation of Ontario (Polo) Chair in the Department of Medicine at the University of Toronto. He is an Adjunct Professor in the Department of Medicine at the University of Alberta and a Co-Director of the Canadian VIGOUR Centre (CVC). He is a consultant to the Canadian Heart Research Centre (CHRC).

<b>Name:</b>	<b>Koenig, Wolfgang</b>
<b>Organization:</b>	Deutsches Herzzentrum München, Technische Universität München, Germany
<b>Title(s):</b>	Professor of Medicine/ Cardiology
<b>Designations/Certificates:</b>	MD, FRCP, FESC, FACC, FAHA Board certified in internal medicine, cardiology and intensive care medicine
<b>Contact Info:</b>	+49-89-1218-4025 <a href="mailto:koenig@dhm.mhn.de">koenig@dhm.mhn.de</a>

<p><b>Specific Areas of Research Interest and Experience in Clinical Trials:</b></p> <ul style="list-style-type: none"> <li>• Evaluation of novel biomarkers for cardiometabolic diseases</li> <li>• Genomics of cardiometabolic diseases</li> <li>• Inflammation, hemostasis and atherogenesis/atherosclerosis</li> <li>• Clinical pharmacology of cardiovascular active compounds</li> <li>• Clinical epidemiology of cardiovascular diseases</li> <li>• Member of the Steering Committee in various clinical trials in cardiometabolic diseases (e.g. JUPITER, STABILITY, CANTOS, DalOutcomes, GLAGOV, PROMINENT, COLCOT, DalGenE, etc.)</li> </ul>
<p><b>Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:</b></p> <ul style="list-style-type: none"> <li>• See above.</li> </ul>

<p><b>Bio:</b></p> <p>Wolfgang Koenig is a Professor of Medicine/Cardiology at the University of Ulm Medical School, Germany. He is a board-certified internist and interventional cardiologist specialised in intensive care medicine and has extensive experience in the molecular epidemiology of cardiovascular diseases. A former Director of the WHO-MONICA Augsburg Myocardial Infarction Register, Professor Koenig has held multiple clinical positions at the University of Ulm Medical Center. In April 2015 he joined the Deutsches Herzzentrum München, Technische Universität München and became an established investigator of the Munich Heart Alliance within the German Centre for Cardiovascular Research (DZHK) and is the Head of the Cardiometabolic Unit. Professor Koenig also serves on the steering committee of multiple large, international randomised clinical trials testing innovative targets in cardiovascular medicine. His research investigates the molecular basis of atherothrombogenesis including the interrelationship between hemostasis, inflammation, and atherothrombotic complications. He also has a particular interest in the clinical pharmacology of cardiovascular active compounds, and the clinical epidemiology of cardiovascular disorders, focusing on the identification and evaluation of new biomarkers for cardiometabolic diseases. Between 2008–2012, he ranked sixth among the most frequently cited German speaking researchers in cardiovascular disease and has an H-Index of 89. In 2014 he received the Rudolf Schönheimer Award from the German Atherosclerosis Society.</p>
---

<b>Name:</b>	<b>Mookadam, Farouk</b>
<b>Organization:</b>	Mayo Clinic, USA
<b>Title(s):</b>	Professor, College of Medicine Mayo Consultant, Cardiovascular Diseases Medical Director, Cardio-Oncology Practice Associate Chair Research, Department of Medicine Associate Program Director, Internal medicine Residency
<b>Designations/Certificates:</b>	MD FRCPC FACC MSc(HRM)
<b>Contact Info:</b>	Mayo Clinic Mayo Clinic Building Concourse 13400 E Shea Blvd 85255 TEL: 480 301 6801 FAX:48- 301 8018 <a href="mailto:Mookadam.farouk@mayo.edu">Mookadam.farouk@mayo.edu</a>

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Cardio-Oncology
- Echocardiography and Metabolic Syndrome
- Echocardiography and epicardial fat as a risk factor
- ONTARGET TRANSCEND studies Project officer; advisory group; adverse events group; trial design
- Formal masters in health research McMaster university
- 200 PUBMED indexed manuscripts; 13 book chapters

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Trial Design
- Research Methodology
- Recruitment strategies



<b>Name:</b>	<b>Nicolau, José Carlos</b>
<b>Organization:</b>	Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, USP, Sao Paulo, BR (Heart Institute (InCor), University of Sao Paulo Medical School), Brazil
<b>Title(s):</b>	Professor of Medicine
<b>Designations/Certificates:</b>	MD, PhD, FACC
<b>Contact Info:</b>	<a href="mailto:corjnicolau@incor.usp.br">corjnicolau@incor.usp.br</a> ; <a href="mailto:josecarlosnicolau@incor.usp.br">josecarlosnicolau@incor.usp.br</a> ; <a href="mailto:corclaudia@incor.usp.br">corclaudia@incor.usp.br</a> Phones: +55-11-26615058/26615196; Cell +55-11-871514117

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Coronary Artery Disease
- Acute Coronary Syndromes
- Platelet aggregability/antiplatelet therapy (main)
- Inflammation/anti-inflammatory drugs
- Left ventricular remodeling
- Diabetes/hyperglycemia/anti-diabetic drugs
- Hypolipidemic drugs

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Experience in clinical and mechanistic trials

**Bio:**

José C. Nicolau is Professor of Medicine at the University of São Paulo Medical School, Director of the Acute Coronary Disease Unit of the Heart Institute (InCor) in São Paulo, Brazil, and Coordinator of the Cardiology Residency Program of the same Institution. Professor Nicolau's main area of research includes the broad spectrum of coronary artery disease (mainly ACS), including hyperglycemia, LV remodeling, platelet reactivity, and antithrombotic therapy. He has participated in dozens of international multicenter clinical trials, serving as a member of their Steering and/or Executive Committees, and/or as National Lead Investigator in 49 of them.

Professor Nicolau has participated in a number of guidelines of the Brazilian Society of Cardiology, being the editor/chairman of the Brazilian guidelines on non-ST-elevation acute coronary syndromes, and one of the coordinators of the Brazilian guidelines on ST-elevation myocardial infarction. He has authored or coauthored more than 380 original articles in indexed journals and book chapters and he has also been senior editor of 4 books: Acute Coronary Syndromes, Cardiology Intensive Care, Intensive Care and Emergencies – How to Treat, and Practical Approaches in Cardiology. He is an editorial board member/reviewer for several national and international publications, as European Heart Journal, International Journal of Cardiology, Diabetes Care, American Heart Journal, American Journal of Cardiology, and Arquivos Brasileiros de Cardiologia e Revista da Sociedade de Cardiologia do Estado de São Paulo. Additionally, he is Advisor of the Journal of the American College of Cardiology, and Abstract Grader for the European Society of Cardiology, American College of Cardiology and American Heart Association, Brazilian Society of Cardiology and São Paulo Society of Cardiology Congresses.

A Fellow of the American College of Cardiology since 1994, Dr. Nicolau is also a member of several international societies. In Brazil, he has been an active member of local medical societies, serving as President of the São Paulo Society of Cardiology and Scientific Director of the Brazilian Society of Cardiology, among other positions.

<b>Name:</b>	<b>Rosenson, Robert S.</b>
<b>Organization:</b>	Icahn School of Medicine at Mount Sinai, USA
<b>Title(s):</b>	Professor of Medicine (Cardiology) Director of Cardiometabolic Disorders Co-Editor-in-Chief Cardiovascular Drugs and Therapy
<b>Designations/Certificates:</b>	MD, FACC, FACP, FAHA, FESC, FCCP
<b>Contact Info:</b>	+ 1 917-836-0029 (cell) +1- 212-659-8721 (office) <a href="mailto:robert.rosenson@mssm.edu">robert.rosenson@mssm.edu</a> The Mount Sinai Medical Centre - 5 East 98th Street, 3rd Floor New York, NY 10029-6574

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Clinical trials with novel lipoprotein modifying and anti-inflammatory therapies.
- Translational based studies using novel approaches to investigate mechanisms of human disease with particular emphasis on lipoproteins, inflammation and thrombosis.  
Global principal investigator in multiple phase II and III trials with novel lipoprotein-modifying agents.

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Biocellular inflammatory pathways in collaboration with Sascha Goonewardena, MD at University of Michigan.
- HDL proteomics in collaboration with Jay Heinecke, MD at University of Washington Seattle.  
Blood rheology and assessment of microvascular perfusion in humans.

**Bio:**

Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Director of Cardiometabolic Disorders at Mount Sinai Heart, New York, New York.

He is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from *Chicago* magazine, and named New York Top Doc from 2015-2018. Dr. Rosenson was named recipient of the Simon Dack Award for outstanding scholarship by the *Journal of the American College of Cardiology* in 2015, 2016 and 2017; and received the Jan J. Kellerman Memorial Award by the International Academy of Cardiology in 2016 for distinguished contributions in the field of cardiovascular disease prevention.

Dr. Rosenson served as principal investigator (PI) on a number of studies funded by the National Institutes of Health, and Global PI for pharmaceutical-funded, multicenter drug trials including PLASMA I, PLASMA II, FRANCIS, BANTING and METCHNIKOFF. He has authored more than 300 journal articles published in peer-reviewed journals, and 600 electronic publications for UpToDate Medicine. Dr Rosenson is co-Editor in Chief for *Cardiovascular Drugs and Therapy*, Section Editor on Metabolic Disorders for the *Journal of the American College of Cardiology*, and Section Editor on Lipid Disorders for *UpToDate*.

<b>Name:</b>	<b>Udell, Jacob</b>
<b>Organization:</b>	Women's College Hospital, Canada
<b>Title(s):</b>	Scientist, Women's College Research Institute Cardiologist, Women's College Hospital, and Peter Munk Cardiac Centre Toronto General Hospital Assistant Professor, Division of Cardiology, Department of Medicine, Faculty of Medicine, University of Toronto
<b>Designations/Certificates:</b>	MD, MPH, FRCPC
<b>Contact Info:</b>	416-804-1977 <a href="mailto:jay.udell@utoronto.ca">jay.udell@utoronto.ca</a> Women's College Hospital, 76 Grenville Street, Toronto, ON M5S 1B1

**Specific Areas of Research Interest and Experience in Clinical Trials:**

- Cardiovascular diabetes outcome trials
- PI, executive committee member, national lead investigator, project officer on a number of multinational cardiovascular outcome trials

**Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:**

- Utilization of electronic health databases to conduct pragmatic trials

**Bio:**

Dr. Udell is Cardiologist and Assistant Professor of Medicine at Women's College Hospital and the Peter Munk Cardiac Center of Toronto General Hospital, teaching hospitals of the University of Toronto. Utilizing the administrative health care databases, registries, and clinical trial populations at their disposal, his team studies the cardiovascular benefits and risks of diabetes and antiplatelet therapies and other novel therapies, including influenza vaccination. His work on innovative cardiovascular risk factor identification and therapies has led to: clinical trial and outcomes publications in the NEJM, JAMA, Circulation, JACC, and Lancet Diabetes; alterations in international cardiovascular practice guidelines; and changes by the FDA and EMA in the label of DPP4 and SGLT2 inhibitors.

<b>Name:</b>	<b>van Diepen, Sean F.P.</b>
<b>Organization:</b>	University of Alberta, Canada
<b>Title(s):</b>	Assistant Professor of Critical Care Medicine and Coronary Intensive Care Unit Co-Director, Divisions of Critical Care and Cardiology Department of Medicine (Cardiology)
<b>Designations/Certificates:</b>	MD, FRCPC (Cardiology and Critical Care Medicine), FAHA
<b>Contact Info:</b>	Office 780-407-6948 Cell 780-937-6997 <a href="mailto:sv9@ualberta.ca">sv9@ualberta.ca</a> University of Alberta Hospital - 2C2 Cardiology Walter MacKenzie Center, 8440-112St Edmonton, AB, T6G 2B7

<p><b>Specific Areas of Research Interest and Experience in Clinical Trials:</b></p> <ul style="list-style-type: none"> <li>• Cardiac surgical care</li> <li>• cardiogenic shock</li> <li>• cardiac arrest</li> <li>• critical care cardiology</li> </ul>
<p><b>Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:</b></p> <ul style="list-style-type: none"> <li>• Dual trained in cardiology and critical care</li> <li>• Clinical research fellowship at the Duke Clinical Research Institute</li> <li>• Clinical Practice in CICU and Cardiovascular surgical ICU</li> <li>• Recent Clinical Trials: Levo-CTS, COMPACT</li> <li>• Recent Registries: Cardiac Critical Care Trials Network, HeartRescue Network</li> </ul>

**Bio:**

Sean van Diepen is an academic Cardiologist-Intensivist with a medical staff appointment at the University of Alberta Hospital. He is co-director of the Coronary Intensive Care Unit at the University of Alberta Hospital. Dr. van Diepen is an Assistant Professor of Critical Care Medicine in the Division of Critical Care (Department of Medicine), and is cross-appointed to the Division of Cardiology (Department of Medicine) at the University of Alberta. He is also a faculty member of the Canadian VIGOUR Centre (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research). Dr. van Diepen completed medical school at the University of Toronto, and after moving west, he undertook Internal Medicine, Cardiology and Critical Care Training at the University of Alberta. He completed a Clinical Research Fellowship at the Duke Clinical Research Institute in Durham, North Carolina and received his Masters of Science in Experimental Medicine from the University of Alberta.

Dr. van Diepen’s clinical interests lie in the care of critically ill cardiac patients. His research interests include critical care cardiology, cardiovascular surgical care, cardiogenic shock, and cardiac arrest care. He has published over 65 papers in peer-reviewed journals, and has given over 55 peer-reviewed presentations at international and regional conferences. Dr. van Diepen serves as an associate editor of the American Heart Journal, and he is also on the editorial board of the Canadian Journal of Cardiology. He is a Fellow of the American Heart Association, and the 2017 recipient of the Excellence in Clinical Teaching Award (in recognition of teaching excellence by University of Alberta cardiology trainees). Dr. van Diepen has supervised seven trainees, and served on two graduate student supervisory committees.

<b>Name:</b>	<b>White, James A.</b>
<b>Organization:</b>	Libin Cardiovascular Institute, University of Calgary, Canada
<b>Title(s):</b>	Director – Stephenson Cardiac Imaging Centre Associate Professor –Medicine Departments of Cardiac Sciences and Radiology
<b>Designations/Certificates:</b>	MD, FRCPC (Internal Medicine and Cardiology)
<b>Contact Info:</b>	Cell: 587-894-1805 <a href="mailto:jawhit@ucalgary.ca">jawhit@ucalgary.ca</a> Suite 0700 SSB, Foothills Medical Centre, Calgary, Alberta, Canada

<p><b>Specific Areas of Research Interest and Experience in Clinical Trials:</b></p> <ul style="list-style-type: none"> <li>• Cardiac Imaging</li> <li>• Cardiovascular Magnetic Resonance (CMR) Imaging</li> <li>• Risk prediction modelling</li> <li>• Sudden Cardiac Death</li> <li>• Cardiac Resynchronization Therapy (CRT)</li> <li>• Late Gadolinium Enhancement (scar) quantification</li> <li>• 4D Cardiac Modelling &amp; Strain analysis</li> <li>• Machine Learning</li> <li>• Randomized controlled trials (Lead PI and Co-PI) evaluating image-guided care strategies</li> <li>• Multi-centre Registries (Lead PI and Co-PI) evaluating risk prediction modelling through phenotype-based patient-specific features</li> <li>• Local PI for numerous NIH-funded clinical trials (HCMR, Ischemia, 4D Flow in Bicuspid Aortic Valve (BAV))</li> <li>• Core laboratory for NIH-funded studies (HCMR (strain sub-study) and BAV (4D flow)) and for CIHR-funded studies (4D cardiac modelling).</li> </ul>
<p><b>Methods/Skills/Techniques That Would be Used to Support Other Trials Within the WNICR Group:</b></p> <ul style="list-style-type: none"> <li>• Core laboratory for CMR-defined endpoints</li> <li>• Experience in Registry data management and standardized data capture for Pragmatic Clinical Trials (Co-Founder and CMO - Cohesic Inc.)</li> <li>• Design of cardiac imaging protocols (primarily CMR) for multi-centre clinical trials</li> </ul>

**Bio:**

Dr. James White is a Cardiologist / Clinician Scientist at the Libin Cardiovascular Institute in Calgary, Alberta, and is Director of the Stephenson Cardiac Imaging Centre. He leads a research program focused on defining the role of Cardiovascular Imaging in Precision Medicine. Dr. White completed his specialty training at Western University, followed by a fellowship in Cardiovascular MRI and Clinical Research at Duke University. After beginning his academic career in London, Ontario, he was recruited to be Director of the Stephenson Cardiovascular Imaging Centre in Calgary, Alberta in 2013. Dr White was an Early Investigator of the Heart and Stroke Foundation, was recently named a Peak Scholar of the University of Calgary, and has over 75 peer-reviewed publications. He has received young investigator awards from both the American College of Cardiology and Canadian Cardiovascular Society and is the immediate past president of the Canadian Society of Cardiovascular MRI. He is leading numerous multi-center initiatives defining the role of Cardiovascular MRI-based phenotyping to improve delivery of ICD and CRT, and to enable personalized care for patients with non-ischemic cardiomyopathy. Dr. White co-founded Cohesic Inc., a successful health technology company delivering HIS-integrated clinical reporting and data management solutions for cardiac diagnostic testing to enable personalized care.